19-255 -Trial of Study Medication as Monotherapy or Combination Therapy or Placebo in Women with Recurrent Cervical Cancer
Status: openA Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Treatment for Cervical Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at clinical.trials@health.southalabama.edu.
Description
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.
Sponsors
This trial is sponsored by Agenus.Principle Investigator
Providers Associated With This Trial
Sub Investigators
View Profile
Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology; Director of Gynecologic Oncology Research LaboratoryView Profile
Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistLeader of Cancer Control and Prevention; Program Director for the Gynecologic Oncology Fellowship; Professor of Interdisciplinary Clinical OncologyView Profile
Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology